| Identification | Back Directory | [Name]
Benzamide, 2-[[3-(acetylamino)-1H-indazol-6-yl]thio]-N-methyl- | [CAS]
2617376-08-4 | [Synonyms]
Benzamide, 2-[[3-(acetylamino)-1H-indazol-6-yl]thio]-N-methyl- | [Molecular Formula]
C17H16N4O2S | [MOL File]
2617376-08-4.mol | [Molecular Weight]
340.4 |
| Hazard Information | Back Directory | [Uses]
CPD-002 is an inhibitor for vascular endothelial growth factor receptor 2 (VEGFR 2), that inhibits angiogenesis through inhibition of VEGFR2/PI3K/AKT signaling pathway. CPD-002 exhibits anti-inflammatory activity and attenuates rheumatoid arthritis[1]. | [in vivo]
CPD-002 (15-60 mg/kg, i.p., once daily for 14 days) exhibits anti-arthritic and anti-angiogenic effects in adjuvant-induced arthritisrats rats model[1]. | Animal Model: | adjuvant-induced arthritis (AIA) Sprague Dawley rats models[1] | | Dosage: | 15-60 mg/kg | | Administration: | i.p., once daily for 14 days | | Result: | Ameliorated paw swelling, joint damage, and synovial angiogenesis. |
| [References]
[1] Jiang F, et al., CPD-002, a novel VEGFR2 inhibitor, relieves rheumatoid arthritis by reducing angiogenesis through the suppression of the VEGFR2/PI3K/AKT signaling pathway. Int Immunopharmacol. 2024 Apr 20;131:111850. DOI:10.1016/j.intimp.2024.111850 |
|
|